$XBI $150.83 -2% 📉
Want to access our searchable database of catalysts and more? Get access to BiopharmIQ for 30 days free, no credit card required. Check it out here!
$RDHL -13% expands ph 2/3 covid-19 study of oral opaganib for severe covid-19 patients to the US. source
$PLX -3% Positive topline results from ph 3 open-label study for Fabry disease. source
$SCPH +1% received meeting minutes from Type A meeting with FDA following CRL. FDA noted the outstanding questions relate to pre-approval inspections and bench testing. No additional clinical data required. Company plans to resubmit NDA in Q3 2021. source